• Clinical Technology
  • Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Nephrology
  • Neurology
  • Pulmonology

7 New Drugs Approved for Primary Care: Q2 2022

News
Slideshow

Another quarter has come and gone, which means Patient Care Online has compiled another list of new drugs approved by the US Food and Drug Administration (FDA) for conditions that are often seen in primary care. Scroll through the slides below to find details on the first and only specific interleukin-23 inhibitor to be approved for the treatment of Crohn disease in adults, the first drug indicated for the treatment for eosinophilic esophagitis, and 5 more.

Missed last quarter's drug roundup? Check out 7 New Drugs Approved for Primary Care: Q1 2022

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Related Content
Roksana Karim, MD, PhD: New Data Support Early Window for Postmenopausal Hormone Therapy / image credit Keck School of Medicine of USC

MHT and Alzheimer Risk: New Evidence for a Critical Window, with Roksana Karim, MD, PhD

Roksana Karim, MD, PhD;Grace Halsey
October 29th 2025
Article

Karim discusses secondary findings from the ELITE trial of timing for estradiol initiation, which reveal a notable impact on Aβ biomarkers of Alzheimer disease.

Weekly Dose Podcast: Depression Risk After Chronic Illness, Vaginal Estradiol Safety, GLP-1 Updates, Cancer Risk Reduction, and Cardiovascular Outcomes

Weekly Dose Podcast: Depression Risk After Chronic Illness, Vaginal Estradiol Safety, GLP-1 Updates, Cancer Risk Reduction, and Cardiovascular Outcomes

Sydney Jennings
September 24th 2025
Podcast

Today's episode covers depression risk after chronic illness, vaginal estradiol safety, GLP-1 updates, cancer risk, and cardiovascular outcomes.

AI-Powered Diabetes Prevention Program Intervention Matches Human Coaching in Landmark Trial

AI-Powered Diabetes Prevention Program Intervention Matches Human Coaching in Landmark Trial

Grace Halsey
October 27th 2025
Article

After 1 year of coaching by the AI app or a DPP-associated coach, reductions in weight and HbA1c and increases in physical activity were equal, an outcome with great promise for scalability.

Weekly Dose Podcast: CRC Screening Uptake, GLP-1 Eligibility in Youth, Women’s Heart Health, and Ultraprocessed Food Risks

Weekly Dose Podcast: CRC Screening Uptake, GLP-1 Eligibility in Youth, Women’s Heart Health, and Ultraprocessed Food Risks

Sydney Jennings
August 28th 2025
Podcast

This week’s podcast episode covers CRC screening, GLP-1 eligibility in youth, women’s heart health, FIT outreach, and ultraprocessed food risks.

FDA Green-Lights Elinzanetant, First Dual NK-1/NK-3 Antagonist, for Moderate to Severe Vasomotor Symptoms of Menopause

FDA Green-Lights Elinzanetant, First Dual NK-1/NK-3 Antagonist, for Moderate to Severe Vasomotor Symptoms of Menopause

Sydney Jennings
October 24th 2025
Article

The novel once-daily nonhormonal therapy offers a new option to offer women who prefer not to take HRT or for whom it is contraindicated.

Menopause: A Constellation of Syndromes / image credit ©Cienpies Design/stock.adobe.com

Menopause: A Constellation of Syndromes Across 13 Body Systems

October 24th 2025
Article

Our short slide show outlines interrelated syndromes of menopause across 13 body systems, implicating therapeutic targets and approaches for clinical practice.

© 2025 MJH Life Sciences

All rights reserved.